CN105534958A - Fesoterodine fumarate slow release capsule and preparation method thereof - Google Patents
Fesoterodine fumarate slow release capsule and preparation method thereof Download PDFInfo
- Publication number
- CN105534958A CN105534958A CN201510949269.9A CN201510949269A CN105534958A CN 105534958 A CN105534958 A CN 105534958A CN 201510949269 A CN201510949269 A CN 201510949269A CN 105534958 A CN105534958 A CN 105534958A
- Authority
- CN
- China
- Prior art keywords
- fumaric acid
- fesoterodine
- acid fesoterodine
- slow releasing
- releasing capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a fesoterodine fumarate slow release capsule and a preparation method thereof. The fesoterodine fumarate slow release capsule is prepared by filling capsule shells with fesoterodine fumarate slow release microspheres; the slow release microspheres comprise fesoterodine fumarate, ethyl cellulose and a release modifier and is prepared by a W / O / W double emulsion method. The fesoterodine fumarate slow release microspheres are freeze-dried and packed into the capsule shells to obtain the fesoterodine fumarate slow release capsule. The invention can effectively avoid the hydrolysis and oxidation of active ingredients in ordinary release tablets, and enhance the stability of the preparation, so as to ensure continuous and regular release of main ingredients after oral administration; and the fesoterodine fumarate slow release capsule has the advantages of easy administration, lasting effect and stable curative effect.
Description
Technical field
The present invention relates to a kind of Western medicine preparation technical field, particularly relate to a kind of fumaric acid fesoterodine slow releasing capsule, also relate to the preparation method of this slow releasing capsule.
Background technology
Fumaric acid fesoterodine chemistry 2-(1R by name)-3-(diisopropylaminoethyl)-1-phenyl propyl)-4-(methylol) phenyl isobutyl acid esters, be a bladder excessive activities syndrome new drug of Pfizer's exploitation, the l0 month in 2008 is approved listing by U.S. FDA.Fumaric acid fesoterodine belongs to prodrug, and be 5-hydroxymethyl tolterodine (5-HMT) through rapid hydrolysis in blood after oral, the latter is also the active metabolite of tolterodine.5-HMT is muscarinic receptor antagonist, and urinary system smooth muscle of bladder and exciting salivary secretion are shunk in the effect of muscarinic receptor, and fesoterodine is by suppressing the mechanisms play effect of these bladder receptors.
The dosage form of going on the market abroad is at present slow releasing tablet, 1 time on the one oral medication, there are 4mg and 8mg two kinds of specifications, general treatment can obtain obvious curative effects after 2 ~ 8 weeks, but fumaric acid fesoterodine is easily hydrolyzed and is oxidized, the stability adding plurality of stable agent guarantee preparation is needed in tablet, first fumaric acid fesoterodine is prepared into sustained-release micro-spheres, pharmaceutical pack is rolled in slow-release material, can ensure that sustained drug discharges, microsphere is after lyophilization, reinstall in capsule shells and be prepared into slow releasing capsule, because principal agent is subject to the duplicate protection of slow-release material and capsule shells, principal agent composition can be effectively avoided to be hydrolyzed and to be oxidized, while minimizing stabilizing agent uses, guarantee the stability of preparation.
Ethyl cellulose is a kind of conventional Sustained release coating materials, has good film property, and what also can be used as sustained-release micro-spheres prepares material, and the preparation method of current microsphere has mainly contained O/O method, O/W and W/O/W method.The bag that O/O method and O/W method are mainly used in poorly water soluble drugs carries, and W/O/W fado is used for water soluble drug bag and carries.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of novel fumaric acid fesoterodine oral slow-releasing preparation and preparation method thereof, to avoid hydrolysis and the oxidation of fumaric acid fesoterodine, strengthen the stability of preparation, control the slow releasing of fumaric acid fesoterodine simultaneously, facilitate administration and stablize curative effect.
For solving the problems of the technologies described above, the present invention adopts following technical scheme:
A kind of fumaric acid fesoterodine slow releasing capsule, be filled in capsule shells by fumaric acid fesoterodine sustained-release micro-spheres and form, described sustained-release micro-spheres is by fumaric acid fesoterodine, ethyl cellulose and drug release regulator composition, the mass percent of described fumaric acid fesoterodine is 1% ~ 40%, the mass percent of ethyl cellulose is 1% ~ 50%, the mass percent of drug release regulator is 0 ~ 40%, preferably, the mass percent of described fumaric acid fesoterodine is 5% ~ 30%, the mass percent of ethyl cellulose is 20% ~ 40%, the mass percent of drug release regulator is 0 ~ 15%, wherein, when the percent mass mark of drug release regulator is 0%, represent not containing drug release regulator.
Further, described fumaric acid fesoterodine sustained-release micro-spheres is prepared from by W1/O/W2 double emulsion.
Wherein, the mean diameter of described fumaric acid fesoterodine sustained-release micro-spheres is 0.5 micron ~ 500 microns, preferably 10 microns ~ 250 microns.
Wherein, the viscosity of described ethyl cellulose is 10cps ~ 600cps, preferred 20cps ~ 100cps.
Wherein, described drug release regulator is one or more in PVA, PVP, PEG, sodium bicarbonate, sodium chloride, phosphate, glycerol, propylene glycol, mannitol, preferred PVP and PVA, more preferably PVP.
Fumaric acid fesoterodine slow releasing capsule capsule of the present invention can be prepared as follows:
(1) fumaric acid fesoterodine, ethyl cellulose and drug release regulator is measured according to prescription, the mass percentage concentration being made into drug release regulator that drug release regulator and fumaric acid fesoterodine is dissolved in the water is the solution of 0% ~ 20%, as interior aqueous phase W1, ethyl cellulose is dissolved in organic solvent and is made into the solution that mass percentage concentration is 1% ~ 50%, as organic facies O, the solution that mass percentage concentration is 0% ~ 20% is made into, as outer aqueous phase W2 by soluble in water for surfactant;
(2) add in organic facies O by interior aqueous phase W1, ultrasonic emulsification forms uniform colostrum W1/O;
(3) colostrum W1/O adds in outer aqueous phase W2, and ultrasonic emulsification forms emulsion W1/O/W2;
(4) emulsion W1/O/W2 is by stirring volatilization removing organic solvent, after isolating solid, cleans 3 times with water, namely obtains fumaric acid fesoterodine sustained-release micro-spheres after drying;
(5) the fumaric acid fesoterodine sustained-release micro-spheres that step (4) is obtained is incapsulated in shell, obtain fumaric acid fesoterodine slow releasing capsule.
The mass percentage concentration of drug release regulator of the present invention is 0% ~ 20%, preferably 5% ~ 10%.
Organic solvent of the present invention is not miscible with water and volatile organic solvent, can be selected from ethyl acetate, dichloromethane or chloroform, preferred dichloromethane.
Surfactant cocoa of the present invention is selected from one of following: PVA, Tween80, Tween20, sodium lauryl sulphate, dodecylbenzene sodium sulfonate, polyoxyethylene 40 fatty acid ester or glyceryl monostearate, preferred Tween20 and PVA, state that surfactant is soluble in water is made into the solution that mass percentage concentration is 0% ~ 20%, the mass percentage concentration of preferred surfactant is 2% ~ 6%.
In the present invention, the ratio of organic facies O and outer aqueous phase W2 is generally 1:1 ~ 1:200, preferred 1:5 ~ 1:15.
Ultrasonic emulsification equipment described in the present invention is ultrasonic emulsification instrument, and ultrasonic power is 100W ~ 500W, preferred 200W ~ 400W, and ultrasonic time is 3min ~ 20min, preferred 5min ~ 10min.
Except fumaric acid fesoterodine, the present invention can also be applicable to the preparation of other water soluble drug ethyl cellulose slow release capsules.
The fumaric acid fesoterodine slow releasing capsule that the present invention relates to has following beneficial effect:
(1) the present invention prepares by W1/O/W2 double emulsion the microsphere that ethyl cellulose bag carries fumaric acid fesoterodine, microsphere is incapsulated in shell and is prepared into slow releasing capsule, both can ensure that sustained drug discharged, principal agent composition can be avoided again to be hydrolyzed and oxidation, while minimizing stabilizing agent uses, guarantee the stability of preparation;
(2) selected adjuvant is common, and preparation technology is simple, and mild condition, does not need large-scale instrument, is easy to promote.
Detailed description of the invention
In order to be illustrated more clearly in advantage and disadvantage of the present invention; below in conjunction with embodiment, the specific embodiment of the present invention is further described; those skilled in the art are to be understood that; specifically described content is illustrative and nonrestrictive below, should not limit the scope of the invention with this.
The preparation of embodiment 1 fumaric acid fesoterodine slow releasing capsule
(1) get fumaric acid fesoterodine 0.1g to be dissolved in 2mL water and to be made into the solution that mass percentage concentration is 5%, as interior aqueous phase W1, be that the ethyl cellulose 5.7g of 45cps is dissolved in 10mL dichloromethane and is made into the solution that mass percentage concentration is 30% by viscosity, as organic facies O, 3.1gPVA is dissolved in the solution being made into mass percentage concentration 3% in 100mL water, as outer aqueous phase W2;
(2) add in organic facies O by interior aqueous phase W1, power 300W ultrasonic emulsification 8min forms uniform colostrum W1/O;
(3) colostrum W1/O adds in outer aqueous phase W2, and power 300W ultrasonic emulsification 8min forms emulsion W1/O/W2;
(4) emulsion W1/O/W2 is by stirring volatilization removing organic solvent, after isolating solid, cleans 3 times with water, namely obtains fumaric acid fesoterodine sustained-release micro-spheres after drying;
(5) the fumaric acid fesoterodine sustained-release micro-spheres that step (4) is obtained is incapsulated in shell, obtain fumaric acid fesoterodine slow releasing capsule.
The preparation of embodiment 2 fumaric acid fesoterodine slow releasing capsule
(1) get fumaric acid fesoterodine 0.5g and 0.25gPVPK30 to be dissolved in 2mL water and to be made into the solution that fumaric acid fesoterodine and PVPK30 mass percentage concentration are respectively 20% and 10%, as interior aqueous phase W1, be that the ethyl cellulose 5.7g of 45cps is dissolved in 10mL dichloromethane and is made into the solution that mass percentage concentration is 30% by viscosity, as organic facies O, 3.1gPVA is dissolved in the solution being made into mass percentage concentration 3% in 100mL water, as outer aqueous phase W2;
(2) add in organic facies O by interior aqueous phase W1, power 300W ultrasonic emulsification 8min forms uniform colostrum W1/O;
(3) colostrum W1/O adds in outer aqueous phase W2, and power 300W ultrasonic emulsification 8min forms emulsion W1/O/W2;
(4) emulsion W1/O/W2 is by stirring volatilization removing organic solvent, after isolating solid, cleans 3 times with water, namely obtains fumaric acid fesoterodine sustained-release micro-spheres after drying;
(5) the fumaric acid fesoterodine sustained-release micro-spheres that step (4) is obtained is incapsulated in shell, obtain fumaric acid fesoterodine slow releasing capsule.
The preparation of embodiment 3 fumaric acid fesoterodine slow releasing capsule
(1) get fumaric acid fesoterodine 0.6g and 0.3gPVPK30 to be dissolved in 2mL water and to be made into the solution that fumaric acid fesoterodine and PVPK30 mass percentage concentration are respectively 30% and 15%, as interior aqueous phase W1, be that the ethyl cellulose 5.7g of 45cps is dissolved in 10mL dichloromethane and is made into the solution that mass percentage concentration is 30% by viscosity, as organic facies O, 3.1gPVA is dissolved in the solution being made into mass percentage concentration 3% in 100mL water, as outer aqueous phase W2;
(2) add in organic facies O by interior aqueous phase W1, power 300W ultrasonic emulsification 8min forms uniform colostrum W1/O;
(3) colostrum W1/O adds in outer aqueous phase W2, and power 300W ultrasonic emulsification 8min forms emulsion W1/O/W2;
(4) emulsion W1/O/W2 is by stirring volatilization removing organic solvent, after isolating solid, cleans 3 times with water, namely obtains fumaric acid fesoterodine sustained-release micro-spheres after drying.
(5) the fumaric acid fesoterodine sustained-release micro-spheres that step (4) is obtained is incapsulated in shell, obtain fumaric acid fesoterodine slow releasing capsule.
The preparation of embodiment 4 fumaric acid fesoterodine slow releasing capsule
(1) get fumaric acid fesoterodine 0.5g and 0.25gPVPK30 to be dissolved in 2mL water and to be made into the solution that fumaric acid fesoterodine and PVPK30 mass percentage concentration are respectively 20% and 10%, as interior aqueous phase W1, be that the ethyl cellulose 3.34g of 45cps is dissolved in 10mL dichloromethane and is made into the solution that mass percentage concentration is 20% by viscosity, as organic facies O, 2gPVA is dissolved in the solution being made into mass percentage concentration 2% in 100mL water, as outer aqueous phase W2;
(2) add in organic facies O by interior aqueous phase W1, power 200W ultrasonic emulsification 10min forms uniform colostrum W1/O;
(3) colostrum W1/O adds in outer aqueous phase W2, and power 200W ultrasonic emulsification 10min forms emulsion W1/O/W2;
(4) emulsion W1/O/W2 is by stirring volatilization removing organic solvent, after isolating solid, cleans 3 times with water, namely obtains fumaric acid fesoterodine sustained-release micro-spheres after drying.
(5) the fumaric acid fesoterodine sustained-release micro-spheres that step (4) is obtained is incapsulated in shell, obtain fumaric acid fesoterodine slow releasing capsule.
The preparation of embodiment 5 fumaric acid fesoterodine slow releasing capsule
(1) get fumaric acid fesoterodine 0.5g and 0.25gPVPK30 to be dissolved in 2mL water and to be made into the solution that fumaric acid fesoterodine and PVPK30 mass percentage concentration are respectively 20% and 10%, as interior aqueous phase W1, be that the ethyl cellulose 8.9g of 45cps is dissolved in 10mL dichloromethane and is made into the solution that mass percentage concentration is 40% by viscosity, as organic facies O, 6.4gPVA is dissolved in the solution being made into mass percentage concentration 6% in 100mL water, as outer aqueous phase W2;
(2) add in organic facies O by interior aqueous phase W1, power 400W ultrasonic emulsification 5min forms uniform colostrum W1/O;
(3) colostrum W1/O adds in outer aqueous phase W2, and power 400W ultrasonic emulsification 5min forms emulsion W1/O/W2;
(4) emulsion W1/O/W2 is by stirring volatilization removing organic solvent, after isolating solid, cleans 3 times with water, namely obtains fumaric acid fesoterodine sustained-release micro-spheres after drying.
(5) the fumaric acid fesoterodine sustained-release micro-spheres that step (4) is obtained is incapsulated in shell, obtain fumaric acid fesoterodine slow releasing capsule.
The drug release determination of test example 1 embodiment 1 ~ 5 gained fumaric acid fesoterodine slow releasing capsule
According to " slow, controlled release preparation guideline " in Pharmacopoeia of the People's Republic of China version (two) annex in 2010, with 0.25% sodium lauryl sulphate for release medium, the accurate fumaric acid fesoterodine slow releasing capsule appropriate (about 100mg) taken obtained by embodiment 1 ~ 5 respectively, measure according to Pharmacopoeia of the People's Republic of China version annex XD first method in 2010, measure peak area by HPLC method, calculate drug level and cumulative release percentage rate.Measurement result is in table 1.
Table 1 embodiment 1 ~ 5 fumaric acid fesoterodine slow releasing capsule release investigation table (dissolution medium: 0.25% sodium lauryl sulphate)
Test example 2 embodiment 1 gained fumaric acid fesoterodine slow releasing capsule influence factor tests
Example 1 gained fumaric acid fesoterodine slow releasing capsule, carries out high temperature (60 DEG C) test, high humidity (75%) test and illumination (4500Lx ± 500Lx) test respectively.Respectively at sampling in 5,10 days, test by capsule Basic Evaluation elementary item, the results are shown in Table 2
Table 2 fumaric acid fesoterodine slow releasing capsule influence factor result of the test
Test example 3 embodiment 1 gained fumaric acid fesoterodine slow releasing capsule stability test.
(1) accelerated test: Example 1 gained fumaric acid fesoterodine slow releasing capsule, is 40 DEG C ± 2 DEG C in temperature, places in the climatic chamber of humidity 75% ± 5%, samples in the 0th, 1,2,3 and June, detects, the results are shown in Table 3.
(2) long-term stable experiment: Example 1 gained fumaric acid fesoterodine slow releasing capsule, is 25 DEG C ± 2 DEG C in temperature, places in the climatic chamber of humidity 60% ± 5%, in the 0th, 3,6,9, December sampling, detect, the results are shown in Table 4.
Table 3 embodiment 1 gained fumaric acid fesoterodine slow releasing capsule accelerated test result
Table 4 embodiment 1 gained fumaric acid fesoterodine slow releasing capsule long-term stable experiment result
As known from Table 1, fumaric acid fesoterodine slow releasing capsule is slowly evenly release in 20h, and from table 2-4, fumaric acid fesoterodine slow releasing capsule has good stability.
Obviously; the above embodiment of the present invention is only for example of the present invention is clearly described; and be not the restriction to embodiments of the present invention; for those of ordinary skill in the field; can also make other changes in different forms on the basis of the above description; here cannot give exhaustive to all embodiments, every belong to technical scheme of the present invention the apparent change of extending out or variation be still in the row of protection scope of the present invention.
Claims (8)
1. a fumaric acid fesoterodine slow releasing capsule, be filled in capsule shells by fumaric acid fesoterodine sustained-release micro-spheres and form, described sustained-release micro-spheres is made up of fumaric acid fesoterodine, ethyl cellulose and drug release regulator, it is characterized in that:
(1) by mass percentage, fumaric acid fesoterodine is 1% ~ 40%, and ethyl cellulose is 1% ~ 50%, and drug release regulator is 0 ~ 40%;
(2) prepared by W1/O/W2 double emulsion.
2. according to fumaric acid fesoterodine slow releasing capsule according to claim 1, it is characterized in that: described sustained-release micro-spheres is made up of fumaric acid fesoterodine, ethyl cellulose and drug release regulator, by mass percentage, fumaric acid fesoterodine is 5% ~ 30%, ethyl cellulose is 20% ~ 40%, and drug release regulator is 0 ~ 15%.
3., according to slow releasing capsule according to claim 2, it is characterized in that the viscosity of described ethyl cellulose is 10cps ~ 600cps.
4., according to fumaric acid fesoterodine slow releasing capsule according to claim 2, it is characterized in that described drug release regulator is one or more in PVA, PVP, PEG, sodium bicarbonate, sodium chloride, phosphate, glycerol, propylene glycol, mannitol.
5. prepare the method for the fumaric acid fesoterodine slow releasing capsule described in any one of claim 1 ~ 4, comprise the following steps:
(1) fumaric acid fesoterodine, ethyl cellulose and drug release regulator is measured according to prescription, the mass percentage concentration being made into drug release regulator that drug release regulator and fumaric acid fesoterodine is dissolved in the water is the solution of 0% ~ 20%, as interior aqueous phase W1, ethyl cellulose is dissolved in organic solvent and is made into the solution that mass percentage concentration is 5% ~ 30%, as organic facies O, the solution that mass percentage concentration is 0% ~ 20% is made into, as outer aqueous phase W2 by soluble in water for surfactant;
(2) add in organic facies O by interior aqueous phase W1, ultrasonic emulsification forms uniform colostrum W1/O;
(3) colostrum W1/O adds in outer aqueous phase W2, and ultrasonic emulsification forms emulsion W1/O/W2;
(4) emulsion W1/O/W2 is by stirring volatilization removing organic solvent, after isolating solid, cleans 3 times with water, namely obtains fumaric acid fesoterodine sustained-release micro-spheres after drying;
(5) the fumaric acid fesoterodine sustained-release micro-spheres that step (4) is obtained is incapsulated in shell, obtain fumaric acid fesoterodine slow releasing capsule.
6. according to fumaric acid fesoterodine slow releasing capsule according to claim 5, it is characterized in that described organic solvent is for not miscible with water and volatile organic solvent, can be selected from one of following: ethyl acetate, dichloromethane or chloroform.
7. according to fumaric acid fesoterodine slow releasing capsule according to claim 5, it is characterized in that described surfactant can be selected from one of following: PVA, Tween80, Tween20, sodium lauryl sulphate, dodecylbenzene sodium sulfonate, polyoxyethylene 40 fatty acid ester or glyceryl monostearate.
8., according to fumaric acid fesoterodine slow releasing capsule according to claim 5, it is characterized in that described ultrasonic emulsification equipment is ultrasonic emulsification instrument, ultrasonic power is 100W ~ 500W, and ultrasonic time is 3min ~ 20min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510949269.9A CN105534958A (en) | 2015-12-18 | 2015-12-18 | Fesoterodine fumarate slow release capsule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510949269.9A CN105534958A (en) | 2015-12-18 | 2015-12-18 | Fesoterodine fumarate slow release capsule and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105534958A true CN105534958A (en) | 2016-05-04 |
Family
ID=55814889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510949269.9A Pending CN105534958A (en) | 2015-12-18 | 2015-12-18 | Fesoterodine fumarate slow release capsule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105534958A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111346060A (en) * | 2020-03-23 | 2020-06-30 | 山东达因海洋生物制药股份有限公司 | Ethyl cellulose taste-masking microsphere with controllable release speed and preparation thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579362A (en) * | 2012-02-23 | 2012-07-18 | 浙江工业大学 | Felodipine slow-release microspheres and preparation method thereof |
| US20130172411A1 (en) * | 2010-03-22 | 2013-07-04 | Cadila Healthcare Limited | Stable pharmaceutical compositions comprising fesoterodine |
-
2015
- 2015-12-18 CN CN201510949269.9A patent/CN105534958A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130172411A1 (en) * | 2010-03-22 | 2013-07-04 | Cadila Healthcare Limited | Stable pharmaceutical compositions comprising fesoterodine |
| CN102579362A (en) * | 2012-02-23 | 2012-07-18 | 浙江工业大学 | Felodipine slow-release microspheres and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111346060A (en) * | 2020-03-23 | 2020-06-30 | 山东达因海洋生物制药股份有限公司 | Ethyl cellulose taste-masking microsphere with controllable release speed and preparation thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104274409B (en) | A kind of medicine microspheres for being easy to swallow and preparation method thereof | |
| TWI285118B (en) | Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof | |
| KR20160045728A (en) | Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose | |
| CZ18599A3 (en) | Formulation with multiple unit of tramadol | |
| ES2610966T3 (en) | Formulations comprising 2-amino-2- [2- (4-octyl-phenyl) -ethyl] -propane-1,3-diol | |
| HU230771B1 (en) | Sustained release vitamin composition | |
| CN103889455B (en) | Stabilize Eperisone medical component and the sustained release preparation containing above-mentioned constituent | |
| CN103717223A (en) | Sustained/release pharmaceutical composition comripising choline alfoscerate or pharmaceutically acceptable salt thereof and method for manufacturing the same | |
| JPWO2005102291A1 (en) | Seamless capsules containing water-soluble active ingredients | |
| US20230240999A1 (en) | Novel fine particle coating (drug-containing hollow particle and method for manufacturing same) | |
| BRPI0719236A2 (en) | FENILALKYL CARBAMATE COMPOSITIONS | |
| JP7303221B2 (en) | Enteric coated softgel capsule | |
| CN104825483B (en) | A kind of probenecid sustained release tablets and preparation method | |
| JP2022514569A (en) | Amorphous sparsentan composition | |
| ES2756711T3 (en) | Stabilized formulations of CNS compounds | |
| KR20170086063A (en) | Pharmaceutical bead formulations comprising dimethyl fumarate | |
| AU2017348941B2 (en) | Pharmaceutical compositions comprising a fumaric acid ester and method for the preparation thereof | |
| CN104706604A (en) | Perampanel freeze-dried oral disintegrating tablet and preparation method thereof | |
| ES2417330T3 (en) | Pharmaceutical mini-tablets for the sustained release of flecainide acetate | |
| KR101659983B1 (en) | Melt-extruded release controlled pharmaceutical composition and oral dosage form comprising the same | |
| RU2015143993A (en) | SOLID MEDICINAL FORMS WITH ANTI-ETERNAL ACTION, WITH SLOW DELIVERY | |
| CN105534958A (en) | Fesoterodine fumarate slow release capsule and preparation method thereof | |
| JP2005537240A (en) | Spherical pellet containing active ingredients soluble in water | |
| CN103169685A (en) | Butylphthalide controlled release preparation and preparation method thereof | |
| US20080193537A1 (en) | Morphine Sulfate Formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160504 |